Literature DB >> 25177625

Diclofenac-serratiopeptidase combination induced stevens - johnson syndrome - a rare case report with review of literature.

Saibal Moitra1, Sukanta Sen2, Indranil Banerjee2, Prasanta Das3, Santanu K Tripathi4.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCAR) which are frequently caused by exposure to drugs and cause significant morbidity and mortality. A careful literature search revealed that only a few reports of diclofenac induced and one case of serratiopeptidase associated case report of SJS or TEN have been published till date. However, to our knowledge, no case report of diclofenac-serratiopeptidase combination induced SJS have been published till date. In this backdrop, we describe the first case of a 62-year-old woman who developed diffuse, erythematous rash on face, trunk and both extremities which later turned into blisters following five day treatment with diclofenac and serratiopeptidase combination. There was extensive ulceration of buccal, genital and ocular mucosa. The body surface area involvement of the patient at the time of presentation was 9%. A provisional diagnosis of SJS was made by the treating physician. After administration of intravenous antibiotic, topical antiseptic, anti-histamine, topical lubricants, fluid therapy and parenteral nutrition patient recovered and were discharged.

Entities:  

Keywords:  Causality assessment, Stevens-johnson syndrome (SJS); Severe cutaneous adverse reactions (SCAR); Toxic epidermal necrolysis (TEN)

Year:  2014        PMID: 25177625      PMCID: PMC4149131          DOI: 10.7860/JCDR/2014/9509.4610

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

Review 2.  Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  P Michele Williams; Robert J Conklin
Journal:  Dent Clin North Am       Date:  2005-01

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

5.  Stevens-Johnson syndrome: a case report.

Authors:  Shishir R Shetty; Laxmikanth Chatra; Prashanth Shenai; Prasanna K Rao
Journal:  J Oral Sci       Date:  2010-06       Impact factor: 1.556

6.  Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo.

Authors:  A Mazzone; M Catalani; M Costanzo; A Drusian; A Mandoli; S Russo; E Guarini; G Vesperini
Journal:  J Int Med Res       Date:  1990 Sep-Oct       Impact factor: 1.671

7.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

8.  Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes.

Authors:  H Assier; S Bastuji-Garin; J Revuz; J C Roujeau
Journal:  Arch Dermatol       Date:  1995-05

Review 9.  Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2013-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.